I am sure that my right hon. Friend shares my concern about the continued inequalities in relation to cardiovascular disease. Will he provide me with an update on what is being done to tackle inequalities not only in the prevalence of the disease but in access to care?
My hon. Friend is absolutely right about the importance of this matter. The inequalities relating to cardiovascular disease have narrowed substantially over the past eight years, and we are well on track for a 40 per cent. reduction in the inequalities gap by 2010. The most important measure—among a range that I have too little time to set out—is the introduction of a vascular health check for everyone between the ages of 40 and 74 on a call-and-recall basis every three years. That programme commenced last month and it will be one of the most important contributors to tackling this disease and to focusing the NHS much more on prevention than on diagnosis and cure.
My right hon. Friend the Secretary of State and I have met Lord Archer to discuss his report, and the Government intend to respond to his findings before the House adjourns for the spring bank holiday recess. The question of a debate is a bit beyond my remit, Mr. Speaker, but I am sure that you heard what the hon. Gentleman said.
As my hon. Friend will know, the Department of Health’s long-held policy is not to fund in cases such as these. However, she has raised details about which the whole House will be concerned and on which it will want to see progress. The Secretary of State has offered to have a meeting with officials and the national advisory council of the Thalidomide Trust to pursue these matters, and I agreed during an Adjournment debate on 31 March to meet the all-party group on thalidomide. My hon. Friend the Member for Gower (Mr. Caton), who chairs the group, is going to write to me with details of the points that he wishes to raise with the Department on behalf of the group. That offers us a way of taking this matter forward.
I will happily look into the case that the hon. Gentleman raises. He will know that foundation trusts come under the remit of Monitor rather than the direct remit of the Department of Health. I would also point out the finances not only of his local hospital but of the NHS in general are in much better shape than they were even just three or four years ago.
May I congratulate my right hon. Friend on the abolition of NHS prescription charges for cancer patients? Will he tell us when the review of long-term conditions that are currently not exempt from such charges will be completed?
My right hon. Friend is right to say that we took the decision on cancer prescriptions as the first step towards looking at other long-term conditions. The first thing we have to do is to define long-term conditions—some very easily slot into that definition and there is no mystery, but there are some cases around the edges that we need to be absolutely sure about. That is why we asked Professor Ian Gilmore to carry out this report. I understand that his work will be completed in the summer.
I can confirm that. It is the type of project that we want to succeed because it is the type of project that the local NHS feels is absolutely essential. As far as I am aware, nothing has changed from the position that obtained when we met in my office a few months ago.
I am grateful to my hon. Friend for writing to me, following the last Health questions. I wrote to him earlier today about this. The local health trust says that giving this contract—[Interruption.] Postmen can deliver very quickly. The gloriously named Sunlight Laundry, which will take over this project, can do everything being done at the moment but at a lower price. I am sure that it does not want its dirty linen to be washed in public, so what I have done in my letter to my hon. Friend is to offer a meeting with the Under-Secretary of State for Health, my hon. Friend the Member for Brentford and Isleworth (Ann Keen). I hope that it can take place shortly.
What we have done since the allocations last December—it was a two-year allocation of 5.5 per cent. each year and included the ability to draw down £800 million of surplus—is to say that there is a message here. It comes from the chief executive of the NHS as well, and it is that the NHS has to prepare for a time when we will not have such spectacular increases in growth. We brought the level of investment up to within touching distance of the European average. Now that we are there, at around 9 per cent., it is inconceivable—irrespective, incidentally, of the economic situation—that such large increases will continue. The message from the chief executive of the NHS and from me is that we need to think in a five-year time frame, including not just the next two years, but the three years to follow.
We cannot say at this stage what the expenditure will be in the NHS, but we can say that it will continue to be our absolute priority. As the Prime Minister told the Royal College of Nursing yesterday, we hope very much to ensure that there are real-terms increases over the coming years, although they may not be at the same level as in the past.
My hon. Friend has raised a very important point, which will concern all Members, about the drugs that are apparently being made available, particularly those containing benzylpiperazine. The Medicines and Healthcare products Regulatory Agency is pursuing the matter, and is trying to establish whether the drugs need to be defined as medicines when they are sold either on the internet or over the counter. In addition, the Advisory Council on the Misuse of Drugs is considering the whole issue and, in particular, whether certain products should now be banned. When we receive its recommendations, I shall be more than happy to inform my hon. Friend of them, because the present position is resulting in deadly drugs being available when they should not be.
The Minister of State will know from our recent Adjournment debate how important it is for thousands of my constituents to be guaranteed access to GPs registered in England so that they, residents of England, can be treated under the rules of the English NHS rather than those of the Welsh health service. Is he able to update me following his recent visit to my constituency and his meeting with the chief executive of my local primary care trust?
I am well aware of the issue, because the hon. Gentleman has raised it with me on a number of occasions. I am not sure that anyone could say with any confidence that thousands of people may be in this position, but there is no doubt that a number of them may be. Having discussed the matter with the chief executive of NHS Gloucestershire during my visit to the hon. Gentleman’s constituency last week, I can inform him that the primary care trust will seek to resolve the case that he raised with it, involving a particular couple. It also intends to survey all Gloucestershire residents registered with GPs in Wales to establish how many of them might wish to register with GPs in England, with a view to providing more GPs in the part of the hon. Gentleman’s constituency where a problem exists.
Why are NHS children-only dental contracts still operating with private dentists? Is that not an unacceptable legacy of practice in the past, when parents were persuaded to take up private treatment on the basis that their children would continue to receive NHS treatment?
My hon. Friend is a member of the Select Committee on Health, which produced a very good report on dentistry, and that is one of the points that it raised. I have asked Professor Jimmy Steele to examine all the issues, including registration and children’s services, and to report back very quickly. I hope that at the same time we can produce a response to the Committee’s report, because I think that it made an important contribution to the debate about the future of dentistry.
One in five people in the United Kingdom suffers from hay fever, especially at this time of year, and one in three people will develop an allergy at some point in their lives. What are the Government doing to raise awareness among GPs of immunotherapy as a treatment that can tackle causes, not just symptoms, and bring lasting relief to many allergy sufferers?
I thank my right hon. Friend for his visit to Chorley hospital, but may I draw his attention to an issue that affects the whole of Lancashire and, indeed, the whole country? I refer to the funding of mental health services. We all know that mental health care is a poor relation. What can my right hon. Friend do to help pensioners who suffer from mental illness? Can he secure extra funds and support, and ensure that provision is seamless between social services, primary care trusts and hospitals themselves?
I very much enjoyed my visit to my hon. Friend’s constituency; I saw some very good things going on there. On mental health, last year’s OECD report said that Britain is in the lead on mental health services—in the lead on the number of psychiatrists and psychiatric nurses per head of population, and in the lead in having the lowest suicide rates since records began. We want to do more, however. The roll-out of psychological therapies is crucial to people of all age groups, but especially pensioners, and 3,600 psychological therapists are being trained up in what Lord Layard describes as the biggest single improvement to mental health since the NHS began.
In the interests of value for money in the NHS, may I ask Ministers to look into the prescription of what are known as “specials” by GPs? A local pharmacist has written to me giving an example of a product consisting of 50 g of Betnovate cream, which costs £2.86, and 450 g of E45, costing £5.39; the total cost of the mixed cream was £347.88. Clearly, there is money being wasted here; will Ministers please look into this?